MedTrace Logo

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02367066 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-06-23

Study results available
· View outcomes & findings →

Summary

A study to assess the Pharmacodynamics of oral AR-C165395XX after Administration of Repeated Doses for 3 days in Subjects with Type 2 Diabetes Mellitus

Conditions

Interventions

DRUG

AR-C165395XX

Oral dose of AR-C165395XX (tablets)

OTHER

Placebo

Oral dose of placebo for AR-C165395XX (tablets)

Sponsors & Collaborators

Principal Investigators

  • Liliana Uribe-Bruce, MD, MCI · Profil Institute for Clinical Research, Inc.

  • Stanko Skrtic, MD, PhD · AstraZeneca R&D Mölndal

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02367066 on ClinicalTrials.gov